Overview
- Researchers found an inactivated form of the enzyme GRK2 builds into aggregates in brains from dementia patients and mouse models, and those aggregates damage mitochondria and boost amyloid‑beta production.
- In cell and aged‑mouse experiments the team tested several molecules and identified compound 10 as the most effective at stopping GRK2 aggregation and preserving neuron and mitochondrial function.
- Treated mice showed less amyloid‑beta deposition, slower neurodegeneration, longer survival and extra‑neural benefits such as improved heart markers and fewer age‑related grey hairs.
- The study reporting these preclinical findings was published in Cell Reports Medicine, ETH Zurich has filed for a patent on compound 10, and investigators are now seeking an industry partner to advance development.
- Significant translational steps remain before any human benefit can be claimed, including safety testing, toxicology, dosing studies and formal clinical trials, but the work adds a new, biologically grounded target for Alzheimer’s drug searches.